EUCTR2005-002880-98-AT进行中（未招募）不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mg
GP-Pharm s.a.0 个研究点目标入组 120 人开始时间: 2005年10月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Males at least 18 years of age or above, with histologically proven carcinoma of prostate, who might benefit from medical androgen deprivation therapy; life expectancy of at least 1 year;World Health Organization/Eastern Cooperative or Group (WHO/ECOG) performance status of 0, 1, or 2; adequate renal function at screening as defined by serum creatinine less than or equal to 1.6 times the ULN (upper limit of normal) for the clinical laboratory; adequate and stable hepatic function as defined by bilirubin less than or equal to 1.5 times the ULN and transaminases (i.e. SGOT, SGPT) less than or equal to 2.5 times the ULN for the clinical laboratory at screening; ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study; signed written informed consent prior to inclusion in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence of brain metastases, spinal cord compression, evidence of severe urinary tract obstruction with threatening urinary retention and excruciating, severe pain from extensive osseous deposits in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms; testosterone levels < 1.5 ng/mL at screening; previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g. antibody therapies, tumor-vaccines), biological response modifiers (e.g. cytokines) within 3 months of baseline; previous hormonal therapy for treatment of prostate cancer, such as LHRH analogues (e.g. Lupron®, Zoladex®); previous treatment with AR-receptor blockers, such as Casodex®, Fugerel®, Megace®, Androcur®; previous orchiectomy, adrenalectomy or hypophysectomy; previous prostatic surgery (e.g. radical prostatectomy, TUR-P) within 2 weeks of baseline; previous local therapy to the primary tumor with a curative attempt other than surgery (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks of baseline; any investigational drug within 5 half-lives of its physiological action or 3 months, whichever is longer, of baseline; administration of 5-a-reductase inhibitors (Proscar®, Avodart®, Propecia®) within 3 months of baseline; OTC or alternative medical therapies which have an estrogenic or anti-androgenic effect within the 3 months of baseline; hematological parameters (RBC, total and differential WBC count, platelet count, hemoglobin, hematocrit) outside 20% of the upper or lower limits of normal (ULN, LLN) for the clinical laboratory at screening; co-existent malignancy; uncontrolled congestive heart failure, myocardial infarction or a coronary vascular procedure or significant symptomatic cardiovascular disease(s) within 6 months of baseline; resting uncontrolled hypertension or symptomatic hypotension within 3 months of baseline; venous thrombosis within 6 months of baseline; insulin-dependent diabetes mellitus; history of drug and/or alcohol abuse within 6 months of baseline; serious concomitant illness(es) or disease(s); patients receiving anticoagulants who have prothrombin and partial thromboplastin times outside of the normal range for the laboratory assays. Patients who are on anticoagulation or antiplatelet medications (e.g. dipyridamole, ticlopidine, warfarin derivatives) who are not receiving a stable dose for 3 months before baseline. Patients who are receiving warfarin-derivative anticoagulants who do not have an International Normalized Ratio (INR) in the therapeutic range for the clinical indication for which the anticoagulant has been prescribed; blood donations/losses within 2 months of baseline, apart from previous prostatic surgery patients (please note that these patients should not be included in the PK group); known hypersensitivity to GnRH, GnRH agonist, including any LHRH analogues, or any excipients of the study formulation; history of immunization within 4 weeks of baseline, flu shots within 2 weeks of baseline, anaphylaxis,skin disease which would interfere with injection site evaluation. Dermatographism will be documented at screening and followed up while on treatment.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgprostate cancerEUCTR2005-002880-98-DEGP-Pharm s.a.160
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgMedDRA version: 6.0Level: LLTClassification code 10007113prostate cancerEUCTR2005-002880-98-HUGP-Pharm s.a.120
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patientsMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2005-002880-98-ESGP-Pharm s.a120
进行中（未招募）
不适用
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - NDprostate cancerEUCTR2005-002880-98-ITGP-PHARM S.A.120
进行中（未招募）
1 期
Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mgMedDRA version: 6.0Level: LLTClassification code 10007113prostate cancerEUCTR2005-002880-98-SKGP-Pharm s.a.160